单吻合口胃旁路术与Roux-en-Y胃旁路术5年疗效与安全性比较(YOMEGA):一项前瞻性、开放标签、非劣效性、随机扩展研究
YOMEGA试验在法国9个中心将253例肥胖患者随机分配至单吻合口胃旁路术(OAGB)或Roux-en-Y胃旁路术(RYGB),5年随访时OAGB组平均超额BMI减少百分比为-75.6%,RYGB组为-71.4%,证实非劣效性;两组2型糖尿病缓解率相似,但OAGB组临床胃食管反流病发生率更高(41% vs 18%)。
要点
- 5年时OAGB组平均超额BMI减少-75.6%,RYGB组-71.4%,证实非劣效性。
- 两组2型糖尿病缓解率相似,营养状况无差异。
- OAGB组临床胃食管反流病发生率41%,高于RYGB组的18%。
核心结论
- OAGB在5年时关于超额BMI减少百分比不劣于RYGB,代谢结局相似。
- OAGB术后临床胃食管反流病发生率高,对其长期后果提出疑问,需进一步研究。
研究设计与样本
- YOMEGA为前瞻性、开放标签、非劣效性、随机试验,在法国9个中心开展。
- 纳入标准为BMI≥40 kg/m²,或BMI≥35 kg/m²且伴有合并症。
- 关键排除标准为严重胃食管反流病或Barrett食管以及既往减重手术史。
- 患者按1:1随机分配至OAGB(一个胃空肠吻合,胆胰支200 cm)或RYGB( alimentary支150 cm,胆支50 cm),按中心分层,区组大小可变。
- 2014年5月13日至2016年3月2日期间,253例患者被随机分配至OAGB(n=129)或RYGB(n=124),其中OAGB组114例和RYGB组118例纳入符合方案分析。
主要发现
- 符合方案人群中,基线平均年龄43.0岁(SD 10.8),平均BMI 44.0 kg/m²(5.6),男性54例(23%),女性178例(77%);207例患者中55例(27%)患有2型糖尿病。
- 5年后,OAGB组平均超额BMI减少百分比为-75.6%(SD 28.1),RYGB组为-71.4%(SD 29.8),平均差异-4.1%(90% CI -12.0至3.7),p=0.0099,证实非劣效性。
- 两组2型糖尿病缓解率相似。
- 营养状况无差异。
- 最常见不良事件为临床胃食管反流病,OAGB组66例中27例(41%)发生,RYGB组76例中14例(18%)发生(p=0.0030)。
关键数值与推荐
- 主要终点为超额BMI减少百分比,在符合方案人群中分析,非劣效性界限为7个百分点,若CI上限小于7个百分点则结论为非劣效。
- 符合方案人群包括接受随机分配技术手术且有数据的患者,排除随访期间重大方案偏离(改变手术技术、死亡或撤回知情同意)的患者。
局限性
- OAGB术后临床胃食管反流病发生率高,对其长期后果提出疑问,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multicentre randomised trial YOMEGA (NCT02139813) comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. METHODS: YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion criteria were BMI of 40 kg/m2 or more, or 35 kg/m2 or more with comorbidities. Key exclusion criteria were severe gastro-oesophageal reflux disease or Barrett's oesophagus and previous bariatric surgery. Patients were randomly assigned (1 :1) to OAGB (one gastrojejunal anastomosis with a 200 cm biliopancreatic limb) or RYGB (with a 150 cm alimentary limb and a 50 cm biliary limb), stratified by centre, with blocks of variable size. The primary endpoint of this extension study was percentage excess BMI loss and was analysed in the per-protocol population, including patients with data who were operated on with the technique randomly assigned to them and excluding patients with major deviations from the protocol during the follow-up (change of surgical technique, death, or withdrawal of consent). Non-inferiority was concluded for the primary endpoint if the upper bound of the CI was less than the non-inferiority limit (7 percentage points). YOMEGA is registered with ClinicalTrials.gov, NCT02139813, and the 5-year follow-up of YOMEGA is registered with ClinicalTrials.gov, NCT05549271. FINDINGS: Between May 13, 2014, and March 2, 2016, 253 patients were randomly assigned to OAGB (n=129) or RYGB (n=124), and from these patients 114 in the OAGB group and 118 in the RYGB group were included in the per-protocol analysis. In the per-protocol population, at baseline, mean age was 43·0 years (SD 10·8), mean BMI was 44·0 kg/m2 (5·6), 54 (23%) patients were male and 178 (77%) were female; 55 (27%) of 207 patients had type 2 diabetes. After 5 years, mean percentage excess BMI loss was -75·6% (SD 28·1) in the OAGB group versus -71·4% (SD 29·8) in the RYGB group, confirming non-inferiority (mean difference -4·1% [90% CI -12·0 to 3·7], p=0·0099). Remission of type 2 diabetes was similar in both groups. Nutritional status did not differ; the most common adverse event was clinical gastro-oesophageal reflux disease, occurring in 27 (41%) of 66 patients in the OAGB group versus 14 (18%) of 76 patients in the RYGB group (p=0·0030). Among serious adverse events, ten (8%) of 127 patients converted from OAGB to RYGB. 171 (68%) of 253 patients were followed up. INTERPRETATION: OAGB was not inferior to RYGB regarding percentage excess BMI loss at 5 years with similar metabolic outcomes. The high rate of clinical gastro-oesophageal reflux disease after OAGB raises questions about its long-term consequences, which need to be further investigated. FUNDING: Medtronic.
引用
- Robert M, Poghosyan T, Maucort-Boulch D, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study. Lancet Diabetes Endocrinol. 2024. PMID: 38452784. doi:10.1016/S2213-8587(24)00035-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。